Scientists at the University of California, San Francisco (UCSF), have discovered how to target a class of molecular switches called GTPases that are involved in a myriad of diseases—from Parkinson’s ...

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science industry, today announced the launch of its biomarker discovery service, ...

Conscience, a non-profit focused on accelerating drug discovery in areas of unmet medical need using open science and radical collaboration, is pleased to announce three recipients and projects have ...